Role of Biomarkers for Detection, Diagnosis and Targeted Therapy of Gynecological Cancers
DOI:
https://doi.org/10.63682/jns.v14i32S.9160Keywords:
Gynecological Cancer, Endometrial cancer, Ovarian Cancer, Cervical Cancer, Uterine Cancer, Gynecological Cancer Biomarkers.Abstract
Cancer is the uncontrollable abnormal division of cell growth, caused due to the varied reasons. Cancer can be expressed in any part of the body, and it is one of the death-causing diseases. Human reproductive organs are commonly damaged by cancer. In particular, the women reproductive system is affected by various cancers including ovarian, cervical, endometrial, vaginal, fallopian tube, and vulvar cancers. Identifying these cancers at earlier stages prevents the damage to the organs. Different biomarkers and aptamers have been generated against the gynecological cancer, which include, ctDNAs, miRNAs, Antigen 125 (CA125), Folate receptor alpha (FOLR1), Transthyretin (TTR), TIM‑3, VEGF, TGF‑α, TRAIL, MCP‑3, IL‑15, PD‑L2, SCF, CTCs, Exosomes, TEPs, cfRNA, HE4, CA125, VEGF, OCCA (for ovarian cancer), EGFR, FGFR1, K-ras (for endometrial cancer), HPV E-16, HPV E-7, HPV E-6, tyrosine, and kinase (for cervical cancer), which help to identify the cancers in woman reproductive organs. This review provided an overview of current and potential biomarkers for gynecological cancer such as ovarian, endometrial and cervical cancers for early detection, diagnosis and targeted therapy.
Downloads
Metrics
References
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008; GLOBOCAN 2008. Int J Cancer. 2010;127:2893e917.
Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC Cancer. Available at: http:// globocan.iarc.fr. Accessed , 2015.
IARC. IARC Handbooks on the Cancer Prevention: Cervix Cancer Screening. Lyon, France: IARC Press; 2005.
IARC. In: IARC Monograph on the Evaluation of Carcinogenic Risks to Humans, Vol. 64: Human Papilloma Viruses. Lyon, France: IARC; 1995.
World Health Organization. Cervical cancer: estimated incidence, mortality, and prevalence worldwide in 2022. Available from: https://www.who. int/news-room/fact-sheets/detail/cervical-cancer [cited 2 March 2024].
Zhu B, Gu H, Mao Z, Beeraka NM, Zhao X, P A Mahesh, Zheng Y, Zhao R, Li S, Manogaran P, Fan R, Nikolenko VN, Wen H, Basappa B, Liu J. Global burden of gynaecological cancers in 2022 and projections to 2050. J Glob Health 2024;14:04155.
Huang, J.; Chan, W.C.; Ngai, C.H.; Lok, V.; Zhang, L.; Lucero-Prisno, D.E., III; Xu, W.; Zheng, Z.-J.; Elcarte, E.; Withers, M.; et al. Worldwide Burden, Risk Factors, and Temporal Trends of Ovarian Cancer: A Global Study. Cancers 2022, 14, 2230.
Deependra Singh, Jerome Vignat, Valentina Lorenzoni, Marzieh Eslahi, Ophira Ginsburg, Beatrice Lauby-Secretan, Marc Arbyn, Partha Basu, Freddie Bray, Salvatore Vaccarella. Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative.Lancet Glob Health. 2023; 11: e197–206
Gao S, Wang J , Li Z , Wang T and Wang J.Global. Trends in Incidence and Mortality Rates of Endometrial Cancer Among Individuals Aged 55 years and Above From 1990 to 2021: An Analysis of the Global Burden of Disease.International Journal of Women’s Health. 2025;17: 651–662
Feng T, Li W, Wang Q , Yang J and Shen F. Global, regional, and national burden of uterine cancer among women aged 50 years and older from 1990 to 2021: a systematic analysis for the global burden of disease study 2021. Journal of Health, Population and Nutrition. 2025; 44:208
World Cancer Research Fund. Endometrial cancer statistics. Available from: https://www.wcrf.org/preventing-cancer/cancer-statistics/ endometrial-cancer-statistics [cited 2 March 2024].
World Ovarian Cancer Coalition. The World Ovarian Cancer Coalition Atlas 2018. Available from: https://worldovariancancercoalition. org/wp-content/uploads/2018/10/THE-WORLD-OVARIAN-CANCER- COALITION-ATLAS-2018.pdf.
de Lang A, Wikström I, Wilander E. Significance of HPV tests on women with cervical smears showing ASCUS. Acta Obstet Gynecol Scand. 2005;84:1001–5.
Gyllensten U, Gustavsson I, Lindell M, Wilander E. Primary high-risk HPV screening for cervical cancer in post-menopausal women. Gynecol Oncol. 2012;125:343–5.
Stenvall H, Wikström I, Backlund I, Wilander E. Accuracy of HPV test of vaginal smear obtained with a novel self-sampling device. Acta Obstet Gynecol Scand. 2007;86:16–21.
Sanner K, Wikström I, Strand A, Lindell M, Wilander E. Self-sampling of the vaginal fluid at home combined with high-risk HPV testing. Br J Cancer. 2009;101:871–4.
Lindell M, Sanner K, Wikström I, Wilander E. Self-sampling of vaginal fluid and high-risk human papillomavirus testing in women aged 50 years or older not attending Papanicolaou smear screening. BJOG. 2012;119:245–8.
Wikström I, Lindell M, Sanner K, Wilander E. Self-sampling and HPV test- ing or ordinary Pap-smear in women not regularly attending screen- ing: a randomised study. Br J Cancer. 2011;105:337–9. d
Moberg M, Gustavsson I, Gyllensten U. Real-time PCR-based system for simultaneous quantification of human papillomavirus types associ- ated with high risk of cervical cancer. J Clin Microbiol. 2003;41:3221–8.
Gustavsson I, Juko-Pecirep I, Backlund I, Wilander E, Gyllensten U. Comparison between the Hybrid Capture 2 and the hpVIR real-time PCR for detection of human papillomavirus in women with ASCUS or low-grade dysplasia. J Clin Virol. 2009;45:85–9.
Gustavsson I, Aarnio R, Myrnäs M, Hedlund-Lindberg J, Taku O, Meiring T, et al. Clinical validation of the HPVIR high-risk HPV test on cervical samples applied on the FTA card according to the inter- national guidelines for human papillomavirus DNA test require- ments for cervical screening. Virol J. 2019;16:107.
Gustavsson I, Lindell M, Wilander E, Strand A, Gyllensten U. Use of FTA card for dry collection, transportation, and storage of cervical cell spec- imen to detect high-risk HPV. J Clin Virol. 2009;46:112–6.
Gustavsson I, Sanner K, Lindell M, Strand A, Olovsson M, Wikström I, et al. Type-specific detection of high-risk human papillomavirus (HPV) in self-sampled cervicovaginal cells applied to FTA elute cartridge. J Clin Virol. 2011;51:255–8.
Maurer K, Luo H, Shen Z, Wang G, Du H, Wang C, et al. Evaluation of a new solid media specimen transport card for high-risk HPV detec- tion and cervical cancer prevention. J Clin Virol. 2016;76:14–9.
Catarino R, Vassilakos P, Bilancioni A, Vanden Eynde M, Meyer-Hamme U, Menoud PA, et al. Randomized comparison of two vaginal self-sam- pling methods for human papillomavirus detection: dry swab versus FTA cartridge. PLoS One. 2015;10:e0143644.
Wang SM, Hu SY, Chen W, Chen F, Zhao FH, He W, et al. Feasibility and accuracy evaluation of three human papillomavirus assays for FTA card-based sampling: a pilot study in cervical cancer screening. BMC Cancer. 2015;15:848.
Luo H, Du H, Maurer K, Belinson JL, Wang G, Liu Z, et al. An evaluation of the Cobas4800 HPV test on cervico-vaginal specimens in liquid ver- sus solid transport media. PLoS One. 2016;11:e0148168. doi
Taku O, Meiring TL, Gustavsson I, Phohlo K, Garcia-Jardon M, Mbulawa ZZA, et al. Acceptability of self-collection for human pap- illomavirus detection in the Eastern Cape, South Africa. PLoS One. 2020;15:e0241781.
Aarnio R, Isacson I, Sanner K, Gustavsson I, Gyllensten U, Olovsson M. Comparison of vaginal self-sampling and cervical sampling by medical professionals for the detection of HPV and CIN2+: a randomized study. Int J Cancer. 2021;148:3051–9.
Sanner K, Wikström I, Gustavsson I, Wilander E, Lindberg JH, Gyllensten U, et al. Daily self-sampling for high-risk human papillomavirus (HR-HPV) testing. J Clin Virol. 2015;73:1–7.
Lindström A, Sanchez Hermansson R, Gustavsson I, Hedlund-Lindberg J, Gyllensten U, Olovsson M. Cervical dysplasia in elderly women performing repeated self-sampling for HPV testing. PLoS One. 2018;13:e0207714.
Hermansson RS, Olovsson M, Gustavsson I, Gyllensten U, Lindkvist O, Lindberg JH, et al. Incidence of oncogenic HPV and HPV-related dysplasia five years after a negative HPV test by self-sampling in elderly women. Infect Agent Cancer. 2022;17:42.
Östensson E, Hellström AC, Hellman K, Gustavsson I, Gyllensten U, Wilander E, et al. Projected cost-effectiveness of repeat high-risk human papillomavirus testing using self-collected vaginal samples in the Swedish cervical cancer screening program. Acta Obstet Gynecol Scand. 2013;92:830–40.
Aarnio R, Östensson E, Olovsson M, Gustavsson I, Gyllensten U. Cost- effectiveness analysis of repeated self-sampling for HPV testing in pri- mary cervical screening: a randomized study. BMC Cancer. 2020;20:645.
Berggrund M, Gustavsson I, Aarnio R, Hedlund-Lindberg J, Sanner K, Wikström I, et al. HPV viral load in self-collected vaginal fluid samples as a predictor for the presence of cervical intraepithelial neoplasia. Virol J. 2019;16:146.
Gyllensten U, Sanner K, Gustavsson I, Lindell M, Wikström I, Wilander E. Short-time repeat high-risk HPV testing by self-sampling for screening of cervical cancer. Br J Cancer. 2011;105:694–7.
Gustavsson I, Aarnio R, Berggrund M, Hedlund-Lindberg J, Strand AS, Sanner K, et al. Randomised study shows that repeated self-sam- pling and HPV test has more than twofold higher detection rate of women with CIN2+ histology than Pap smear cytology. Br J Cancer. 2018;118:56–64.
World Health Organization. Self-care interventions for health: WHO consolidated guideline. Available from: https://www.who.int/publica- tions/i/item/WHO-SRH-23.1 [cited 17 April 2023].
Bruni L, Serrano B, Roura E, Alemany L, Cowan M, Herrero R, et al. Cervical cancer screening programmes and age-specific coverage estimates for 202 countries and territories worldwide: a review and synthetic analy- sis. Lancet. 2022;10:e1115–27.
World Health Organization. WHO prequalifies additional HPV test expanding options as countries pursue cervical cancer elimination. Available from: https://www.who.int/news/item/14-06-2023-who-pre- qualifies-additional-hpv-test-expanding-options-as-countries-pur- sue-cervical-cancer-elimination [cited 14 June 2023].
Spayne J, Hesketh T. Estimate of global human papillomavirus vac- cination coverage: analysis of country-level indicators. BMJ Open. 2021;11:e052016.
Oliveira CM, Fregnani JH, Carvalho JP, Longatto-Filho A, Levi JE. Human papillomavirus geno- types distribution in 175 invasive cer- vical cancer cases from Brazil. BMC Cancer 2013;13:357.
Chong PP, Asyikin N, Rusinahayati M, et al. High preva- lence of human papillomavirus DNA detected in cervical swabs from women in southern Selangor, Malay- sia. Asian Pac J Cancer Prev 2010;11:1645e51.
Venceslau EM, Bezerra MM, Lopes ACM, et al. HPV detection using primers MY09/MY11 and GP5+/GP6+ in patients with cyto- logic and/or colposcopic changes. J Bras Patol Med Lab 2014;50:280e5.
Chan PK, Zhang C, Park JS, et al. Geographical distribution and onco- genic risk association of human papil- lomavirus type 58 E6 and E7 sequence variations. Int J Cancer 2013;132: 2528e36.
Chen AA, Heideman DA, Boon D, et al. Human papillomavirus 45 genetic variation and cervical cancer risk worldwide. J Virol 2014;88: 4514e21.
Alsbeih G, Al-Harbi N, El-Sebaie M, Al-Badawi I. HPV prevalence and genetic predisposition to cervical cancer- in Saudi Arabia. Infect Agents Cancer 2013;8:15.
Senapathy JG, Umadevi P, Kannika PS. The present scenario of cervical cancer control and HPV epi- demiology in India: an outline. Asian Pac J Cancer Prev 2011;12:1107e15.
Jancik S, Drabek J, Radzioch D, Hajduch M. Clinical relevance of KRAS in human cancers. J Biomed Biotechnol 2010;2010:150960.
Janku F, Lee JJ, Tsimberidou AM, et al. PIK3CA mutations frequently coexist with RAS and BRAF muta- tions in patients with advanced can- cers. PLoS One. 2011;6:e22769.
Lida K, Nakayama K, Rahman MT, et al. EGFR gene amplification is related to adverse clinical outcomes in cervical squamous cell carcinoma, making the EGFR pathway a novel therapeutic target. Br J Cancer 2011;105:420e7.
Abu-Rustum N, et al. Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023;21(2):181–209.
Narimatsu H, Sawaki H, Kuno A, Kaji H, Ito H, Ikehara Y. A strategy for discovery of cancer glyco-biomarkers in serum using newly developed technologies for glycoproteomics. FEBS J 2010;277:95–105.
Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 2009; 10:327–40.
Menon U, Gentry-Maharaj A, Burnell M, Singh N, Ryan A, Karpinskyj C, et al. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2021;397:2182–93.
Bast RC, Han CY, Lu Z, Lu KH. Next steps in the early detection of ovarian cancer. Commun Med. 2021:1:36.
Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, et al. Sensitivity and specificity of multimodal and ultrasound screen- ing for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009;10:327–40. doi: 10.1016/S1470-2045(09)70026-9
Lycke M, Kristjansdottir B, Sundfeldt K. A multicenter clinical trial vali- dating the performance of HE4, CA125, risk of ovarian malignancy algo- rithm and risk of malignancy index. Gynecol Oncol. 2018;151:159–65.
Jacobs IJ, Menon U, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi JK, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2016;387:945–56.
Tian C, Wen SB, Zhao CY, Yan XN, Du JX. Comparative diagnostic accuracy of the IOTA SRR and LR2 scoring systems for discriminating between malignant and benign adnexal masses by junior physicians in Chinese patients: a retrospective observational study. BMC Womens Health. 2023;23:27–9.
Lycke M, Ulfenborg B, Lauesgaard MJ, Kristjansdottir B, Sundfeldt K. Consideration should be given to smoking, endometriosis, renal function (eGFR) and age when interpreting CA125 and HE4 in ovarian tumor diagnostics. Clin Chem Lab Med. 2021;59:1954–62.
Ding L, Zhou YX, He C, Ai JY, Lan GL, Xiong HF, et al. Elevated CA125 levels are associated with adverse clinical outcomes in acute pancreati- tis: a propensity score-matched study. Pancreatology. 2020;20:789–94.
Coleman RL, Herzog TJ, Chan DW, Munroe DG, Pappas TC, Smith A, et al. Validation of a second-generation multivariate index assay for malig- nancy risk of adnexal masses. Am J Obstet Gynecol. 2016;215:82.e1–11.
Enroth S, Berggrund M, Lycke M, Broberg J, Lundberg M, Assarsson E, et al. High throughput proteomics identifies a high-accuracy 11 plasma protein biomarker signature for ovarian cancer. Commun Biol. 2019;2:221.
Enroth S, Ivansson E, Lindberg JH, Lycke M, Bergman J, Reneland A, et al. Data-driven analysis of a validated risk score for ovarian cancer identifies clinically distinct patterns during follow-up and treatment. Commun Med. 2022;2:13.
Gyllensten U, Hedlund-Lindberg J, Svensson J, Manninen J, Öst T, Ramsell J, et al. Next-generation plasma proteomics identifies high-precision biomarker candidates for ovarian cancer. Cancers (Basel). 2022;14:1757.
Ivansson E, Lindberg JH, Stålberg K, Sundfeldt K, Gyllensten U, Enroth S. Large-scale proteomics reveals precise biomarkers for detection of ovarian cancer in symptomatic women. Sci Rep. 2024;14:17288.
Álvez MB, Edfors F, von Feilitzen K, Zwahlen M, Mardinoglu A, Edqvist PH, et al. Next-generation pan-cancer blood proteome profiling using proximity extension assay. Nat Commun. 2023;14:13.
Lindberg JH, Widgren A, Ivansson E, Gustavsson I, Stålberg K, Gyllensten U, et al. Toward ovarian cancer screening with protein biomarkers using dried, self-sampled cervico-vaginal fluid. iScience. 2024;27:109001.
van Nagell JR Jr, Miller RW, DeSimone CP, Ueland FR, Podzielinski I, Goodrich ST, et al. Long-term survival of women with epithelial ovarian cancer detected by ultrasonographic screening. Obstet Gynecol 2011;118:1212–21.
Sørensen SS, Mosgaard BJ. Combination of cancer antigen 125 and carcinoembryonic antigen can improve ovarian cancer diagnosis. Dan Med Bull 2011;58:A4331.
Su F, Lang J, Kumar A, Ng C, Hsieh B, Suchard MA, et al. Validation of candidate serum ovarian cancer biomarkers for early detection. Biomark Insights 2007;2:369–75.
Nosov V, Su F, Amneus M, Birrer M, Robins T, Kotlerman J, et al. Validation of serum biomarkers for detection of early-stage ovarian cancer. Am J Obstet Gynecol 2009;200:639.e1–5.
Visintin I, Feng Z, Longton G, Ward DC, Alvero AB, Lai Y, et al. Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res 2008;14:1065–72.
Chen H, Hardy TM, Tollefsbol TO. Epigenomics of ovarian cancer and its chemoprevention. Front Genet 2011;2:67.
Soto-Reyes E, Gonza´lez-Barrios R, Cisneros-Soberanis F, Herrera- Goepfert R, Pe´rez V, Cantu´ D, et al. Disruption of CTCF at the miR-125b1 locus in gynecological cancers. BMC Cancer 2012; 12:40.
Kosaka N, Ochiya T. Unraveling the mystery of cancer by secretory microRNA: horizontal microRNA transfer between living cells. Front Genet 2011;2:97.
Gallo A, Tandon M, Alevizos I, Illei GG. The majority of microRNAs detectable in serum and saliva is concentrated in exosomes. PLoS ONE 2012;7:e30679.
Hu G, Drescher KM, Chen XM. Exosomal miRNAs: biological proper- ties and therapeutic potential. Front Genet 2012;3:56.
La€sser C. Exosomal RNA as biomarkers and the therapeutic potential of exosome vectors. Expert Opin Biol Ther 2012;12 Suppl 1:S189–97.
Kharaziha P, Ceder S, Li Q, Panaretakis T. Tumor cell-derived exo- somes: a message in a bottle. Biochim Biophys Acta 2012;1826: 103–11.
Krutovskikh VA, Herceg Z. Oncogenic microRNAs (OncomiRs) as a new class of cancer biomarkers. BioEssays 2010;32:894–904.
Kuhlmann JD, Rasch J, Wimberger P, Kasimir-Bauer S. microRNA and the pathogenesis of ovarian cancer—a new horizon for molec- ular diagnostics and treatment? Clin Chem Lab Med 2012;50: 601–15.
Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, et al. RAS is regulated by the let-7 microRNA family. Cell 2005; 120:635–47.
Pasic MD, Olkhov E, Bapat B, Yousef GM. Epigenetic regulation of kallikrein-related peptidases: there is a whole new world out there. Biol Chem 2012;393:319–30.
Gallagher MF, Heffron CC, Laios A, O'Toole SA, Ffrench B, Smyth PC, et al. Suppression of cancer stemness p21-regulating mRNA and microRNA signatures in recurrent ovarian cancer patient samples. J Ovarian Res 2012;5:2.
Cheng W, Liu T, Wan X, Gao Y, Wang H. MicroRNA-199a targets CD44 to suppress the tumorigenicity and multidrug resistance of ovarian cancer-initiating cells. FEBS J 2012;279:2047–59.
Wang K, Bodempudi V, Liu Z, Borrego-Diaz E, Yamoutpoor F, Meyer A, et al. Inhibition of mesothelin as a novel strategy for targeting cancer cells. PLoS ONE 2012;7:e33214.
Li J, Liang S, Jin H, Xu C, Ma D, Lu X. Tiam1, negatively regulated by miR-22, miR-183 and miR-31, is involved in migration, invasion and viability of ovarian cancer cells. Oncol Rep 2012;27:1835–42.
Peng DX, Luo M, Qiu LW, He YL, Wang XF. Prognostic implications of microRNA-100 and its functional roles in human epithelial ovarian cancer. Oncol Rep 2012;27:1238–44.
Bagnoli M, De Cecco L, Granata A, Nicoletti R, Marchesi E, Alberti P, et al. Identification of a chrXq27.3 microRNA cluster associated with early relapse in advanced stage ovarian cancer patients. Oncotarget 2011;2:1265–78.
Fu X, Tian J, Zhang L, Chen Y, Hao Q. Involvement of microRNA-93, a new regulator of PTEN/Akt signaling pathway, in regulation of che- motherapeutic drug cisplatin chemosensitivity in ovarian cancer cells. FEBS Lett 2012;586:1279–86.
Slomovitz BM, Broaddus RR, Burke TW, Sneige N, Soliman PT and Wu W: Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J Clin Oncol, 2004; 22: 3126-3132.
Morrison C, Zanagnolo V, Ramirez N, Cohn DE, Kelbick N and Copeland L: HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients. J Clin Oncol. 2006; 24: 2376-2385.
Oda K, Stokoe D, Taketani Y and McCormick F: High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res 65: 10669-10673, 2005.
Salvesen HB, Carter SL, Mannelqvist M, Dutt A, Stefansson IM and Getz G: Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proc Natl Acad Sci USA 106: 4834-4839, 2009.
Ito K, Utsunomiya H, Yaegashi N and Sasano H: Biological roles of estrogen and progesterone in human endometrial carcinoma - new developments in potential endocrine therapy for endometrial cancer. Endocr J 54: 667-679, 2007.
Susini T, Amunni G, Molino C, Carriero C, Rapi S and Branconi F: Ten-year results of a prospective study on the prognostic role of ploidy in endometrial carcinoma: DNA aneuploidy identifies high-risk cases among the so-called ʻlow-riskʼ patients with well and moderately differentiated tumors. Cancer 109: 882-890, 2007.
Colas E, Perez C, Cabrera S, et al: Molecular markers of endo- metrial carcinoma detected in uterine aspirates. Int J Cancer. 2011; 129: 2435-2444.
Amazawa K, Seki K, Matsui H, Kihara M and Sekiya S: Prognostic factors in young women with endometrial carcinoma: a report of 20 cases and review of literature. Int J Gynecol Cancer 10: 212-222, 2000.
Singh M, Zaino RJ, Filiaci VJ and Leslie KK: Relationship of estrogen and progesterone receptors to clinical outcome in meta- static endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 106: 325-333, 2007.
Slomovitz BM, Broaddus RR, Burke TW, Sneige N, Soliman PT and Wu W: Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J Clin Oncol 22: 3126-3132, 2004.
Salvesen HB, Iversen OE and Akslen LA: Prognostic significance of angiogenesis and Ki-67, p53 and p21 expression: a population- based endometrial carcinoma study. J Clin Oncol 17: 1382-1390, 1999.
Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007;133: 647–58.
Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, et al. Effect of screening on ovarian cancer mortality: the prostate, lung, colorectal and ovarian (PLCO) cancer screening randomized con- trolled trial. JAMA 2011;305:2295–303.
Amalric A, et al. Quantifying RNA modifications by mass spectrometry: a novel source of biomarkers in oncology. Crit Rev Clin Lab Sci. 2022;59(1):1–18.
Amort T, Lusser A. Detection of 5-methylcytosine in specific poly(A) RNAs by bisulfite sequencing. Methods Mol Biol. 2017;1562:107–21.
Amort T, et al. Transcriptome-wide detection of 5-methyl- cytosine by bisulfite sequencing. Methods Mol Biol. 2017;1562:123–42.
An Y, Duan H. The role of m6A RNA methylation in cancer metabolism. Mol Cancer. 2022;21(1):14.
Bao G, et al. Comprehensive analysis of the function, immune profiles, and clinical implication of m1A regulators in lung adenocarcinoma. Front Oncol. 2022;12:882292.
Bao Y, et al. Targeting m(6)A reader YTHDF1 augments anti- tumour immunity and boosts anti-PD-1 efficacy in colo- rectal cancer. Gut. 2023;72(8):1497–509.
Barbieri I, Kouzarides T. Role of RNA modifications in cancer. Nat Rev Cancer. 2020;20(6):303–22.
Bedell SL, et al. Cervical cancer screening: past, present, and future. Sex Med Rev. 2020;8(1):28–37.
Burd EM. Human papillomavirus and cervical cancer. Clin Microbiol Rev. 2003;16(1):1–17.
Burki TK. CA-125 blood test in early detection of ovarian cancer. Lancet Oncol. 2015;16(6):e269.
Buskwofie A, David-West G, Clare CA. A review of cervical cancer: incidence and disparities. J Natl Med Assoc. 2020;112(2):229–32.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71: 209 249, 2021.
The International Agency for Research on Cancer: GLOBOCAN 2020: New Global Cancer Data. https://www.uicc.org/news/glob ocan 2020 new global cancer data. Accessed December 17, 2020
Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J and Bray F: Estimates of incidence and mortality of cervical cancer in 2018: A worldwide analysis. Lancet Glob Health 8: e191 203, 2020.
Falcaro M, Castañon A, Ndlela B, Checchi M, Soldan K, Lopez Bernal J, Elliss Brookes L and Sasieni P: The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: A register based observational study. Lancet. 2021; 398: 2084 2092.
Moscicki AB, Schiffman M, Burchell A, Albero G, Giuliano AR, Goodman MT, Kjaer SK and Palefsky J: Updating the natural history of human papillomavirus and anogenital cancers. Vaccine 30 (Suppl 5): F24 F33, 2012.
Tommasino M: The human papillomavirus family and its role in carcinogenesis. Semin Cancer Biol.2014; 26: 13 21.
Hammer A, Rositch A, Qeadan F, Gravitt PE and Blaakaer J: Age specific prevalence of HPV16/18 genotypes in cervical cancer: A systematic review and meta analysis. Int J Cancer 138: 2795 2803, 2016.
Wright JD, Matsuo K, Huang Y, Tergas AI, Hou JY, Khoury Collado F, St Clair CM, Ananth CV, Neugut AI and Hershman DL: Prognostic performance of the 2018 international federation of gynecology and obstetrics cervical cancer staging guidelines. Obstet Gynecol 134: 49 57, 2019.
de Juan A, Redondo A, Rubio MJ, García Y, Cueva J, Gaba L, Yubero A, Alarcón J, Maximiano C and Oaknin A: SEOM clin ical guidelines for cervical cancer (2019). Clin Transl Oncol 22: 270 278, 2020.
Liu SC, Huang EY, Hu CF, Ou YC, ChangChien CC, Wang CJ, Tsai CC, Fu HC, Wu CH and Lin H: Pretreatment factors associated with recurrence for patients with cervical cancer international federation of gynecology and obstetrics stage IB1 disease. Gynecol Obstet Invest 81: 339 345, 2016.
Rodriguez NM: Participatory innovation for human papilloma virus screening to accelerate the elimination of cervical cancer. Lancet Glob Health 9: e582 e583, 2021.
Zhou J, Lei N, Tian W, Guo R, Chen M, Qiu L, Wu F, Li Y and Chang L: Recent progress of the tumor microenvironmental metabolism in cervical cancer radioresistance. Front Oncol 12: 999643, 2022.
Yang J, Cai H, Xiao ZX, Wang H and Yang P: Effect of radio therapy on the survival of cervical cancer patients: An analysis based on SEER database. Medicine (Baltimore) 98: e16421, 2019.
Volkova LV, Pashov AI, Omelchuk NN: Cervical Carcinoma: Oncobiology and Biomarkers. Int J Mol Sci 22: 12571, 2021.
Ballman KV: Biomarker: Predictive or Prognostic? J Clin Oncol 33: 3968 3971, 2015.
Yusufaly TI, Zou J, Nelson TJ, Williamson CW, Simon A, Singhal M, Liu H, Wong H, Saenz CC, Mayadev J, et al: Improved Prognosis of Treatment Failure in Cervical Cancer with Nontumor PET/CT Radiomics. J Nucl Med 63: 1087 1093, 2022.
Chang R, Qi S, Yue Y, Zhang X, Song J and Qian W: Predictive radiomic models for the chemotherapy response in non small cell lung cancer based on computerized tomography images. Front Oncol 11: 646190, 2021.
Dhama K, Latheef SK, Dadar M, Samad HA, Munjal A, Khandia R, Karthik K, Tiwari R, Yatoo MI, Bhatt P, et al: Biomarkers in stress related diseases/disorders: diagnostic, prognostic, and therapeutic values. Front Mol Biosci 6: 91, 2019.
Wang LH, Wu CF, Rajasekaran N and Shin YK: Loss of tumor suppressor gene function in human cancer: An overview. Cell Physiol Biochem 51: 2647 2693, 2018.
Tornesello ML, Faraonio R, Buonaguro L, Annunziata C, Starita N, Cerasuolo A, Pezzuto F, Tornesello AL and Buonaguro FM: The Role of microRNAs, Long Non coding RNAs, and Circular RNAs in Cervical Cancer. Front Oncol 10: 150, 2020.
Gyparaki MT, Basdra EK and Papavassiliou AG: DNA methyla tion biomarkers as diagnostic and prognostic tools in colorectal cancer. J Mol Med (Berl) 91: 1249 1256, 2013.
Charakorn C, Thadanipon K, Chaijindaratana S, Rattanasiri S, Numthavaj P and Thakkinstian A: The association between serum squamous cell carcinoma antigen and recurrence and survival of patients with cervical squamous cell carcinoma: A systematic review and meta analysis. Gynecol Oncol 150: 190 200, 2018.
Dixit CK, Kadimisetty K, Otieno BA, Tang C, Malla S, Krause CE and Rusling JF: Electrochemistry based approaches to low cost, high sensitivity, automated, multiplexed protein immunoassays for cancer diagnostics. Analyst 141: 536 547, 2016.
Füzéry AK, Levin J, Chan MM and Chan DW: Translation of proteomic biomarkers into FDA approved cancer diagnostics: Issues and challenges. Clin Proteomics 10: 13, 2013.
Sun Z, Shi Y, Shen Y, Cao L, Zhang W and Guan X: Analysis of different HER 2 mutations in breast cancer progression and drug resistance. J Cell Mol Med 19: 2691 2701, 2015.
Yang Y, Zhang H, Zhang M, Meng Q, Cai L and Zhang Q: Elevation of serum CEA and CA15 3 levels during antitumor therapy predicts poor therapeutic response in advanced breast cancer patients. Oncol Lett 14: 7549 7556, 2017.
Alegría Baños JA, Jiménez López JC, Vergara Castañeda A, de León DFC, Mohar Betancourt A, Pérez Montiel D, Sánchez Domínguez G, García Villarejo M, Olivares Pérez C, Hernández Constantino Á, et al: Kinetics of HE4 and CA125 as prognosis biomarkers during neoadjuvant chemotherapy in advanced epithelial ovarian cancer. J Ovarian Res 14: 96, 2021.
Islam MS, Afrin S, Jones SI and Segars J: Selective progesterone receptor modulators mechanisms and therapeutic utility. Endocr Rev 41: bnaa012, 2020.
Duffy MJ, Harbeck N, Nap M, Molina R, Nicolini A, Senkus E and Cardoso F: Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM). Eur J Cancer 75: 284 298, 2017.
Chimento A, De Luca A, Avena P, De Amicis F, Casaburi I, Sirianni R and Pezzi V: Estrogen receptors mediated apoptosis in hormone dependent cancers. Int J Mol Sci 23: 1242, 2022.
Seale KN and Tkaczuk KHR: Circulating biomarkers in breast cancer. Clin Breast Cancer 22: e319 e331, 2022.
Banerjee S, Yoon H, Ting S, Tang CM, Yebra M, Wenzel AT, Yeerna H, Mesirov JP, Wechsler Reya RJ, Tamayo P and Sicklick JK: KITlow cells mediate imatinib resistance in gastro intestinal stromal tumor. Mol Cancer Ther, 2021; 20: 2035 2048,
Cayir A. RNA modifications as emerging therapeutic targets. Wiley Interdiscip Rev RNA. 2022;13(4):e1702.
Chantziantoniou N, et al. Inception and development of the papanicolaou stain method. Acta Cytol. 2017;61(4–5):266–80.
Chelmow D, et al. Executive summary of the uterine can- cer evidence review conference. Obstet Gynecol. 2022;139(4):626–43.
Chen SJ, et al. Epigenetically upregulated NSUN2 confers ferroptosis resistance in endometrial cancer via m(5) C modification of SLC7A11 mRNA. Redox Biol. 2024;69:102975.
Cheng J, et al. piR-823, a novel non-coding small RNA, demonstrates in vitro and in vivo tumor suppressive activity in human gastric cancer cells. Cancer Lett. 2012;315(1):12–7.
Jing W, Zhang R, Chen X, Zhang X and Qiu J: Association of glycosylation related genes with different patterns of immune profiles and prognosis in cervical cancer. J Pers Med 13: 529, 2023.
Hishinuma E, Shimada M, Matsukawa N, Li B, Motoike IN, Hagihara T, Shigeta S, Tokunaga H, Saigusa D, Kinoshita K, et al: Identification of predictive biomarkers for diagnosis and radia tion sensitivity of uterine cervical cancer using wide targeted metabolomics. J Obstet Gynaecol Res 49: 2109 2117, 2023.
Kilic S, Cracchiolo B, Gabel M, Haffty B and Mahmoud O: The relevance of molecular biomarkers in cervical cancer patients treated with radiotherapy. Ann Transl Med 3: 261, 2015.
Rashid M, Zadeh LR, Baradaran B, Molavi O, Ghesmati Z, Sabzichi M and Ramezani F: Up down regulation of HIF 1α in cancer progression. Gene 798: 145796, 2021.
Bishop AJ, Allen PK, Klopp AH, Meyer LA and Eifel PJ: Relationship Between Low Hemoglobin Levels and Outcomes After Treatment With Radiation or Chemoradiation in Patients With Cervical Cancer: Has the Impact of Anemia Been Overstated? Int J Radiat Oncol Biol Phys 91: 196 205, 2015.
Domènech M, Hernández A, Plaja A, Martínez Balibrea E and Balañà C: Hypoxia: The cornerstone of glioblastoma. Int J Mol Sci 22: 12608, 2021.
Lei R, Li J, Liu F, Li W, Zhang S, Wang Y, Chu X and Xu J: HIF 1α promotes the keloid development through the activation of TGF beta/Smad and TLR4/MyD88/NF kappaB pathways. Cell Cycle 18: 3239 3250, 2019.
Zhang PC, Liu X, Li MM, Ma YY, Sun HT, Tian XY, Wang Y, Liu M, Fu LS, Wang YF, et al: AT 533, a novel Hsp90 inhibitor, inhibits breast cancer growth and HIF 1α/VEGF/VEGFR 2 mediated angiogenesis in vitro and in vivo. Biochem Pharmacol 172: 113771, 2020.
Apte RS, Chen DS and Ferrara N: VEGF in signaling and disease: Beyond discovery and development. Cell 176: 1248 1264, 2019.
Yoshida K, Suzuki S, Sakata J, Utsumi F, Niimi K, Yoshikawa N, Nishino K, Shibata K, Kikkawa F and Kajiyama H: The upregulated expression of vascular endothelial growth factor in surgically treated patients with recurrent/radioresistant cervical cancer of the uterus. Oncol Lett 16: 515 521, 2018.
Yan B, Ma QF, Tan WF, Cai HN, Li YL, Zhou ZG, Dai X, Zhu FX, Xiong YJ, Xu M, et al: Expression of HIF 1α is a predictive marker of the efficacy of neoadjuvant chemotherapy for locally advanced cervical cancer. Oncol Lett 20: 841 849, 2020.
Hu X, Xing L, Wei X, Liu X, Pang R, Qi L and Song S: Nonangiogenic function of VEGF and enhanced radiosensitivity of HeLa cells by inhibition of VEGF expression. Oncol Res 20: 93 101, 2012.
Zhu P, Ou Y, Dong Y, Xu P and Yuan L: Expression of VEGF and HIF 1α in locally advanced cervical cancer: potential biomarkers for predicting preoperative radiochemotherapy sensitivity and prognosis. Onco Targets Ther 9: 3031 3037, 2016.
Wei LC, Wang N, Shi M, Liu JY, Li JP, Zhang Y, Huang YH, Li X and Chen Y: Clinical outcome observation of preoperative concurrent chemoradiotherapy/radiotherapy alone in 174 Chinese patients with local advanced cervical carcinoma. Onco Targets Ther 6: 67 74, 2013.
Chrysostomou AC, Kostrikis LG. Methodologies of primary HPV testing currently applied for cervical cancer screening. Life (Basel). 2020;10(11):290.
Clark KD, Rubakhin SS, Sweedler JV. Characterizing RNA modifications in single neurons using mass spectrometry. J Vis Exp. 2022;(182):10.3791/63940.
Dai X, et al. Identification of YTH domain-containing pro- teins as the readers for N1-methyladenosine in RNA. Anal Chem. 2018;90(11):6380–4.
Dochez V, et al. Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review. J Ovarian Res. 2019;12(1):28.
Fadare O, et al. Expression of the oncofetal protein IGF2BP3 in endometrial clear cell carcinoma: assessment of frequency and significance. Hum Pathol. 2013;44(8):1508–15.
Fang X, et al. Role of m(5) C RNA methylation regulators in colorectal cancer prognosis and immune microenvironment. J Clin Lab Anal. 2022;36(4):e24303.
Feng Y, et al. Gene signatures and prognostic value of m6A RNA methylation regulators in uterine corpus endome- trial carcinoma. Discov Med. 2021;31(164):111–20.
Funston G, et al. CA125 test result, test-to-diagnosis interval, and stage in ovarian cancer at diagnosis: a retrospective cohort study using electronic health records. Br J Gen Pract. 2021;71(707):e465–72.
Gaffney DK, et al. Consensus recommendations for radiation therapy contouring and treatment of vulvar carcinoma. Int J Radiat Oncol Biol Phys. 2016;95(4):1191–200.
Ghaemmaghami F, Akhavan S. Is postoperative CA125 level in patients with epithelial ovarian cancer reliable to guess the optimality of surgery? Eur J Gynaecol Oncol. 2011;32(2):192–5.
Wang Q, et al. m(1)A Regulator TRMT10C predicts poorer survival and contributes to malignant behavior in gynecological cancers. DNA Cell Biol. 2020a;39(10):1767–78.
Wang Y, et al. Multiomics profile and prognostic gene signa- ture of m6A regulators in uterine corpus endometrial carcinoma. J Cancer. 2020b;11(21):6390–401.
Wang Q, et al. N(6)-methyladenosine METTL3 promotes cervical cancer tumorigenesis and Warburg effect through YTHDF1/HK2 modification. Cell Death Dis. 2020c;11(10):911.
Wang Y, et al. RNA methylation-related genes of m6A, m5C, and m1A predict prognosis and immunotherapy response in cervical cancer. Ann Med. 2023a;55(1):2190618.
Wang C, et al. Identification and validation of m5c-related lncRNA risk model for ovarian cancer. J Ovarian Res. 2023b;16(1):96.
Webb PM, Jordan SJ. Epidemiology of epithelial ovarian can- cer. Best Pract Res Clin Obstet Gynaecol. 2017;41:3–14. Whetstone S, et al. Health disparities in uterine cancer: report from the uterine cancer evidence review conference. Obstet Gynecol. 2022;139(4):645–59.
Woo HH, Chambers SK. Human ALKBH3-induced m(1)A demethylation increases the CSF-1 mRNA stability in breast and ovarian cancer cells. Biochim Biophys Acta Gene Regul Mech. 2019;1862(1):35–46.
Xu F, et al. FBW7 suppresses ovarian cancer development by targeting the N(6)-methyladenosine binding protein YTHDF2. Mol Cancer. 2021;20(1):45.
Xu G, et al. Development of the expression and prognostic sig- nificance of m(5) C-related LncRNAs in breast cancer. Cancer Med. 2023;12(6):7667–81.
Xue C, et al. Role of main RNA modifications in cancer: N(6)- methyladenosine, 5-methylcytosine, and pseudouridine. Signal Transduct Target Ther. 2022;7(1):142.
Yang JC, et al. Association of tRNA methyltransferase NSUN2/ IGF-II molecular signature with ovarian cancer survival. Future Oncol. 2017;13(22):1981–90.
Yang Z, et al. SOX11: friend or foe in tumor preven- tion and carcinogenesis? Ther Adv Med Oncol. 2019;11:1758835919853449.
Yang S, et al. RNA 5-Methylcytosine regulators are associated with cell adhesion and predict prognosis of endometrial cancer. Transl Cancer Res. 2023;12(10):2556–71.
Ye L, et al. Four types of RNA modification writer-related lncRNAs are effective predictors of prognosis and immu- notherapy response in serous ovarian carcinoma. Front Immunol. 2022;13:863484.
Ye L, et al. RNA epigenetic modifications in ovarian cancer: The changes, chances, and challenges. Wiley Interdiscip Rev RNA. 2023;14(5):e1784.
Yi J, et al. Overexpression of NSUN2 by DNA hypomethyla- tion is associated with metastatic progression in human breast cancer. Oncotarget. 2017;8(13):20751–65.
Yin H, et al. RNA m6A methylation orchestrates cancer growth and metastasis via macrophage reprogramming. Nat Commun. 2021;12(1):1394.
Bhatla N, Singhal S. Primary HPV screening for cervi- cal cancer. Best Pract Res Clin Obstet Gynaecol. 2020;65:98–108.
Bi X, et al. METTL3-mediated maturation of miR-126-5p promotes ovarian cancer progression via PTEN-medi- ated PI3K/Akt/mTOR pathway. Cancer Gene Ther. 2021;28(3–4):335–49.
Borgeaud M, et al. Immunotherapy in Urological, Gynecologi- cal and Gastrointestinal Cancers - Current Landscape. Praxis (Bern 1994). 2023;112(3):149–55.
Yu M, et al. NSUN6-mediated 5-methylcytosine modification of NDRG1 mRNA promotes radioresistance in cervical cancer. Mol Cancer. 2024;23(1):139.
Yuan Y, et al. HPV post-infection microenvironment and cervi- cal cancer. Cancer Lett. 2021;497:243–54.
Zeleznik OA, et al. A prospective analysis of circulating plasma metabolites associated with ovarian cancer risk. Cancer Res. 2020;80(6):1357–67.
Zeng Y, et al. Refined RIP-seq protocol for epitranscriptome analysis with low input materials. PLoS Biol. 2018;16(9):e2006092.
Zeng D, et al. TRMT61B rs4563180 G>C variant reduces hepatoblastoma risk: a case-control study of seven medi- cal centers. Aging (Albany NY). 2023;15(15):7583–92.
Zhang C, Liu N. N6-methyladenosine (m6A) modifica- tion in gynecological malignancies. J Cell Physiol. 2022;237(9):3465–79.
Zhang S, McNamara M, Batur P. Cervical Cancer screening: What’s new? Updates for the busy clinician. Am J Med. 2018;131(6):702.e1-702.e5.
Zhang L, et al. FTO demethylates m6A modifications in HOXB13 mRNA and promotes endometrial cancer metastasis by activating the WNT signalling pathway. RNA Biol. 2021;18(9):1265–78.
Zhang X, et al. Research progress on the interaction between oxidative stress and platelets: Another avenue for cancer? Pharmacol Res. 2023;191:106777.
Zhao LY, et al. Mapping the epigenetic modifications of DNA and RNA. Protein Cell. 2020;11(11):792–808.
Zhao S, et al. IGF2BP2 promotes the progression of ovarian endometriosis by regulating m6A-modified MEIS2 and GATA6. Int J Biochem Cell Biol. 2022;152:106296.
Zheng G, et al. ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility. Mol Cell. 2013;49(1):18–29.
Zheng Q, et al. Cytoplasmic m(1)A reader YTHDF3 inhibits trophoblast invasion by downregulation of m(1)A-meth- ylated IGF1R. Cell Discov. 2020;6:12.
Zhu H, et al. ALKBH5 inhibited autophagy of epithelial ovar- ian cancer through miR-7 and BCL-2. J Exp Clin Cancer Res. 2019;38(1):163.
Zhu Z, et al. Detection of plasma exosomal miRNA-205 as a biomarker for early diagnosis and an adjuvant indicator of ovarian cancer staging. J Ovarian Res. 2022;15(1):27.
Zou D, et al. The m(6)A eraser FTO facilitates proliferation and migration of human cervical cancer cells. Cancer Cell Int. 2019;19:321.
Bray F, et al. Geographic and temporal variations in the inci- dence of vulvar and vaginal cancers. Int J Cancer. 2020;147(10):2764–71.
Buchanan TR, Graybill WS, Pierce JY. Morbidity and mor- tality of vulvar and vaginal cancers: Impact of 2-, 4-, and 9-valent HPV vaccines. Hum Vaccin Immunother. 2016;12(6):1352–6
Hay CM, Lachance JA, Lucas FL, et al (2016). Biomarkers p16, HPV, and p53 Predict Recurrence and Survival in Early Stage Squamous Cell Carcinoma of the Vulva. J Low Genit Tract Dis, 20, 252-6.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
